Answers are grounded in this paper and cite their sources.
Examines real-world outcomes of oral decitabine and cedazuridine versus intravenous/subcutaneous hypomethylating agents in MDS patients, suggesting comparable effectiveness.
Background: Decitabine and cedazuridine (DEC-C) is the only oral hypomethylating agent (HMA) approved for myelodysplastic syndromes (MDS) in the United States. The other HMAs approved for MDS, decitabine and azacitidine, are administered intravenously (IV) or subcutaneously (SC). Objectives: This study examined real-world outcomes among MDS patients treated with oral DEC-C compared to IV/SC HMAs. Design: Adult patients diagnosed with MDS who received HMAs as their first treatment on or after July 1, 2020 through February 2024 in ConcertAI’s RWD360 ® electronic medical records dataset linked to open claims were included in the study. Methods: We used propensity score matching (PSM) to balance potential confounders. Kaplan–Meier survival analysis was utilized to compare real-world overall survival (rwOS), acute myeloid leukemia (AML)-free survival, and time to next treatment (rwTTNT) among patients treated with oral DEC-C and IV/SC HMAs. Results: A total of 2101 patients with MDS were included, with 405 treated with oral DEC-C and 1696 treated with IV/SC HMA. After PSM, there were 399 patients in each treatment group; demographic and clinical factors were well balanced. Patients treated with oral DEC-C had a similar median rwOS (22.7 months vs 19.5 months; p = 0.57) and AML-free survival (16.1 months vs 14.3 months; p = 0.10) compared with patients who received IV/SC HMA; however, there were nonsignificant trends in favor of oral DEC-C. The median rwTTNT was significantly longer for the oral DEC-C patients than for the IV/SC HMA patients (9.3 months vs 7.8 months, respectively; p = 0.02). Conclusion: This real-world study is the largest to date to examine clinical outcomes among MDS patients who initiated oral DEC-C compared to IV/SC HMAs. While study results indicate comparable rwOS and AML-free survival among patients treated with oral DEC-C or with IV/SC HMAs, patients treated with oral DEC-C had a significantly longer rwTTNT. These findings support the use of oral DEC-C as an alternative to parenteral HMA therapy.
No takes yet. Share an insight, caveat, or question.
Zeidan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: